Sanofi Genzyme News |

Search

Search

Sanofi

Contact Us Global Locator

Register

Register for email alerts

Newsroom Home

Innovative treatment Cablivi (caplacizumab-yhdp) granted new technology payment (NTAP) for Medicare payment
10/10/19 8:00 am EDT
New England Journal of Medicine publishes data showing improved survival with Jevtana® (cabazitaxel) over second androgen receptor-targeted agent in metastatic castration-resistant prostate cancer
9/30/19 10:34 am EDT
The Lancet Publishes Results from Two Positive Phase 3 Trials of Dupixent® (dupilumab) in Severe Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
9/20/19 7:05 am EDT
CHMP Recommends Approval of Dupixent® (dupilumab) for Severe Chronic Rhinosinusitis with Nasal Polyposis
9/20/19 6:50 am EDT
Educational campaign helps teens and their caregivers tackle the everyday challenges of living with moderate-to-severe atopic dermatitis
9/18/19 7:23 am EDT
Dupixent® (dupilumab) approved by European Commission for adolescents with moderate-to-severe atopic dermatitis
8/6/19 7:31 am EDT
Dupixent® (dupilumab) showed positive topline results in Phase 3 trial of children aged 6 to 11 years with severe atopic dermatitis
8/6/19 7:30 am EDT
FDA to review isatuximab as a potential treatment for relapsed/refractory multiple myeloma
7/10/19 7:00 am EDT
Positive Data from Completed Phase 1/2a study of BIVV001 Presented at ISTH 2019
7/7/19 8:00 am EDT
Easing the Burden for People with Hemophilia
7/3/19 8:00 am EDT
Libtayo® (cemiplimab) approved for advanced cutaneous squamous cell carcinoma in the European Union
7/1/19 10:02 am EDT
CHMP recommends approval of Dupixent® (dupilumab) for moderate-to-severe atopic dermatitis in adolescents
6/28/19 7:02 am EDT
FDA approves Dupixent® (dupilumab) for chronic rhinosinusitis with nasal polyposis
6/26/19 1:34 pm EDT
Sanofi Showcases Hemophilia Pipeline at ISTH 2019
6/24/19 8:50 am EDT
Sanofi and Regeneron announce positive topline Phase 2 results for IL-33 antibody in asthma
6/21/19 7:00 am EDT
Phase 3 trial of isatuximab combination therapy showed 40% reduction in the risk of disease progression or death for patients with relapsed/refractory multiple myeloma
6/2/19 10:46 am EDT
Updated Libtayo® (cemiplimab-rwlc) Results Reinforce Durable and Substantial Response Rates in Advanced Cutaneous Squamous Cell Carcinoma
5/16/19 8:42 am EDT
Sanofi oncology pipeline targeting various cancers highlighted at ASCO 2019
5/15/19 5:01 pm EDT
Dupixent® (dupilumab) Approved for Severe Asthma by European Commission
5/7/19 9:02 am EDT
Relapsing MS Patients Who Received Aubagio® (teriflunomide) Experienced a Reduced Risk of Relapse Regardless of Prior Treatment Status in a Post-Hoc Analysis
5/6/19 9:15 am EDT
Relapsing Remitting MS Patients Who Received Lemtrada® (alemtuzumab) Reported Improvements in Treatment Satisfaction and Health-Related Quality of Life in Clinical Studies
5/6/19 9:00 am EDT
CHMP issues positive opinion for Libtayo® (cemiplimab) in advanced cutaneous squamous cell carcinoma
4/26/19 11:33 am EDT
World Hemophilia Day: Sanofi Genzyme Donation Impacts Patients Across the Globe
4/17/19 7:59 am EDT
Sanofi and Alnylam conclude research and option phase of 2014 rare disease alliance
4/8/19 7:58 am EDT
Sanofi Genzyme Launches Innovative and Educational Audio Adventure Series for People Treated with ALPROLIX®
3/14/19 10:43 am EDT
FDA approves Dupixent® (dupilumab) for moderate-to-severe atopic dermatitis in adolescents
3/11/19 3:48 pm EDT
FDA to undertake priority review of Dupixent® (dupilumab) for adults with inadequately controlled severe chronic rhinosinusitis with nasal polyps
3/8/19 7:36 am EST
CHMP recommends approval of Dupixent® (dupilumab) for asthma indication
3/1/19 8:19 am EST
New analyses to be presented at AAD for Dupixent® (dupilumab) and the burden of atopic dermatitis
3/1/19 7:02 am EST
Positive results presented from two Phase 3 trials of Dupixent® (dupilumab) in severe chronic rhinosinusitis with nasal polyps
2/25/19 12:46 pm EST
Sanofi announces additional data on avalglucosidase alfa in Pompe disease
2/7/19 9:46 am EST
FDA approves Cablivi® (caplacizumab-yhdp), the first Nanobody®-based medicine, for adults with acquired thrombotic thrombocytopenic purpura (aTTP)
2/6/19 12:12 pm EST
Isatuximab Phase 3 trial meets primary endpoint of prolonging progression free survival in patients with relapsed/refractory multiple myeloma
2/5/19 7:02 am EST
Sanofi Presents Research Advances in Rare Genetic Diseases at 15th Annual WORLDSymposium™ 2019
1/30/19 7:27 am EST
New England Journal of Medicine publishes positive results of the pivotal trial of Cablivi® (caplacizumab) for rare blood clotting disorder
1/9/19 5:05 pm EST

Privacy Notice Business Wire NewsHQ℠

infoBox